ValitaCell, has been selected as one of 11 high potential global start-ups to join the prestigious health tech accelerator programme Startup Creasphere.
The Startup Creasphere innovation programme matches global pharmaceutical partners including Roche, Sanofi and Lonza with the Worlds most innovative and disruptive health tech start-ups.
The global healthcare giant Lonza has chosen to collaborate with Valitacell as their chosen high potential start up for the 3-month programme.
Established in 2018, by Roche and Plug and Play, Startup Creasphere is a Munich based Digital Health Accelerator program.
Commenting on the partnership, Dr. Stephanie Davies, Head of Cell Therapy at ValitaCell said
“ValitaCell is delighted to have been chosen by Lonza for this 3 month accelerator programme and we look forward to working with Lonza to transform healthcare together”.